<p>Make a useful contribution for future iGEM teams. Use this page to document that contribution.</p>
<p>If you are making a contribution by adding information to an existing Part or creating a new Part, you must document your contribution on the Part's Main Page on the <ahref="https://parts.igem.org/Main_Page">Registry</a> for your team to be eligible for this criteria. You can use this page to link to that part and include additional information about your contribution.</p>
<hr>
<p>Please see the <ahref="https://competition.igem.org/judging/medals">2024 Medals Page</a> for more information.</p>
</div>
</div>
</div>
<style>
body{
font-family:Arial,sans-serif;
margin:20px;
text-align:center;
}
table{
width:100%;
max-width:1000px;
margin:0auto;
border-collapse:collapse;
}
table,th,td{
border:1pxsolidblack;
}
th,td{
padding:10px;
text-align:justify;
vertical-align:top;
}
th{
background-color:#f2f2f2;
}
@media(max-width:600px){
th,td{
font-size:14px;
}
}
img{
max-height:500rem;
max-width:auto;
display:block;
margin-left:auto;
margin-right:auto;}
figure{
display:table;
padding:5px;
background-color:#fff;
font-size:.875em;
}
figureimg{
display:block;
max-width:100%;
}
figcaption{
display:table-caption;
caption-side:bottom;
background:#fff;
padding:05px5px;}
</style>
<h1>Our Contributions to the iGEM Community</h1>
<divstyle="height: 4rem;"></div>
<pclass="padding"style="text-align: justify;">
The real aim of the project was to set a precedent in the approach of targeting and clearing misfolded proteins using Aptamers. We used Tau as a model and phosphorylation as the label. We have a few registry parts which may be useful to future teams working with Tau or implementing any therapeutics against Tauopathies.
<figcaption>The modified ligand linked base can joined in the 3' terminal of an Aptamer. This is a tool that can convert the activity of the aptamer into that of a PROTAC upon incorporation by Terminal Deoxynucleotidyl Transferase.</figcaption>
